+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Forecast 2024-2030- Product Image
Global Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Forecast 2024-2030- Product Image
Sale

Global Cell & Gene Therapy Biomanufacturing CDMO Market by Component (Cell Therapy, Plasmid DNA, Viral Vector), Phase (Phase 1, Phase 2, Phase 3), Indication - Forecast 2024-2030

  • PDF Icon

    Report

  • 193 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924687
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cell & Gene Therapy Biomanufacturing CDMO Market size was estimated at USD 338.12 million in 2023, USD 485.47 million in 2024, and is expected to grow at a CAGR of 32.53% to reach USD 2,428.90 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cell & Gene Therapy Biomanufacturing CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell & Gene Therapy Biomanufacturing CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Cell Therapy
    • Plasmid DNA
    • Viral Vector
  • Phase
    • Phase 1
    • Phase 2
    • Phase 3
    • Phase 4
  • Indication
    • Cancer
    • Cardiovascular Disease
    • Genetic Disorders
    • Infectious Disease
    • Neurological Disorders
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cell & Gene Therapy Biomanufacturing CDMO Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell & Gene Therapy Biomanufacturing CDMO Market?
  3. What are the technology trends and regulatory frameworks in the Cell & Gene Therapy Biomanufacturing CDMO Market?
  4. What is the market share of the leading vendors in the Cell & Gene Therapy Biomanufacturing CDMO Market?
  5. Which modes and strategic moves are suitable for entering the Cell & Gene Therapy Biomanufacturing CDMO Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cell & Gene Therapy Biomanufacturing CDMO Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing number of R&D activities in cellular and genetic engineering and therapies
5.1.1.2. Increasing need for genetic treatments to cure chronic and genetic disorders
5.1.1.3. Rising number of collaborative activities between CDMOs and major players
5.1.2. Restraints
5.1.2.1. High cost of CDMO services
5.1.3. Opportunities
5.1.3.1. Efforts by CDMOs to incorporate digitalization and AI technologies
5.1.3.2. Rising number of biotechnology and pharmaceutical startups
5.1.4. Challenges
5.1.4.1. Complex regulations surrounding genetic and cell research
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component
6.1. Introduction
6.2. Cell Therapy
6.3. Plasmid DNA
6.4. Viral Vector
7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase
7.1. Introduction
7.2. Phase 1
7.3. Phase 2
7.4. Phase 3
7.5. Phase 4
8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication
8.1. Introduction
8.2. Cancer
8.3. Cardiovascular Disease
8.4. Genetic Disorders
8.5. Infectious Disease
8.6. Neurological Disorders
9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AGC Biologics
13.1.2. Almac Group
13.1.3. Becton, Dickinson and Company
13.1.4. Bio-Rad Laboratories, Inc.
13.1.5. Bio-Techne Corporation
13.1.6. Catalent Inc.,
13.1.7. Charles River Laboratories International Inc.
13.1.8. Danaher Corporation
13.1.9. Endress+Hauser Group Services AG
13.1.10. FUJIFILM Diosynth Biotechnologies
13.1.11. GC Corporation
13.1.12. General Electric Company
13.1.13. Getinge AB
13.1.14. Infors AG
13.1.15. Lonza Group Ltd
13.1.16. Merck KGaA
13.1.17. Miltenyi Biotec B.V. & Co. KG
13.1.18. Patheon Inc.
13.1.19. PCI Pharma Services
13.1.20. Pfizer CentreOne
13.1.21. PIERRE GUERIN
13.1.22. Recipharm AB
13.1.23. Samsung Biologics
13.1.24. Sartorius AG
13.1.25. Thermo Fisher Scientific
13.1.26. uBriGene
13.1.27. WuXi Advanced Therapies
13.1.28. WuXi AppTec
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET RESEARCH PROCESS
FIGURE 2. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2023 VS 2030
FIGURE 3. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET DYNAMICS
FIGURE 7. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
FIGURE 8. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
FIGURE 10. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 10. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 4, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 31. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 32. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 34. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 48. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 49. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 51. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 52. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 57. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 75. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 85. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 86. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 88. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 91. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 103. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 104. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 112. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 115. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 116. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 118. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 119. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 130. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 139. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 148. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
TABLE 149. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET LICENSE & PRICING

Companies Mentioned

  • AGC Biologics
  • Almac Group
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Catalent Inc.,
  • Charles River Laboratories International Inc.
  • Danaher Corporation
  • Endress+Hauser Group Services AG
  • FUJIFILM Diosynth Biotechnologies
  • GC Corporation
  • General Electric Company
  • Getinge AB
  • Infors AG
  • Lonza Group Ltd
  • Merck KGaA
  • Miltenyi Biotec B.V. & Co. KG
  • Patheon Inc.
  • PCI Pharma Services
  • Pfizer CentreOne
  • PIERRE GUERIN
  • Recipharm AB
  • Samsung Biologics
  • Sartorius AG
  • Thermo Fisher Scientific
  • uBriGene
  • WuXi Advanced Therapies
  • WuXi AppTec

Methodology

Loading
LOADING...

Related Topics

Related Reports

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033 - Product Image

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033

  • Report
  • 336 Pages
  • Global
From
Global Biomanufacturing Viral Detection & Quantification Market by Offering Type (Consumables, Instruments, Services), Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Plaque Assay), Application, End User - Forecast 2024-2030 - Product Image

Global Biomanufacturing Viral Detection & Quantification Market by Offering Type (Consumables, Instruments, Services), Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Plaque Assay), Application, End User - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
Global Cell and Gene Therapy CDMO Market: Analysis By Type, Application, Indication, By Region, By Country: Market Insights and Forecast - Product Image

Global Cell and Gene Therapy CDMO Market: Analysis By Type, Application, Indication, By Region, By Country: Market Insights and Forecast

  • Report
  • 260 Pages
  • Global
From
Biomanufacturing Viral Detection and Quantification Market - A Global and Regional Analysis: Focus on Offering Type, Technology, Application, End User, and Region - Analysis and Forecast, 2023-2032 - Product Image

Biomanufacturing Viral Detection and Quantification Market - A Global and Regional Analysis: Focus on Offering Type, Technology, Application, End User, and Region - Analysis and Forecast, 2023-2032

  • Report
  • 273 Pages
  • Global
From
Biomanufacturing Viral Detection and Quantifications Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Biomanufacturing Viral Detection and Quantifications Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.